Free Trial
NASDAQ:IOBT

IO Biotech Q1 2025 Earnings Report

IO Biotech logo
$0.86 -0.03 (-3.36%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$0.89 +0.03 (+3.01%)
As of 04/17/2025 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IO Biotech EPS Results

Actual EPS
N/A
Consensus EPS
-$0.45
Beat/Miss
N/A
One Year Ago EPS
N/A

IO Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

IO Biotech Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 13, 2025
Conference Call Time
7:00AM ET

Conference Call Resources

IO Biotech Earnings Headlines

Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
Piper Sandler Sticks to Their Buy Rating for IO Biotech (IOBT)
See More IO Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like IO Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IO Biotech and other key companies, straight to your email.

About IO Biotech

IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

View IO Biotech Profile

More Earnings Resources from MarketBeat